HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Ashok Malla Selected Research

Polytetrafluoroethylene (Teflon)

7/2015Clinical and functional implications of a history of childhood ADHD in first-episode psychosis.
10/2012Medication adherence mediates the impact of sustained cannabis use on symptom levels in first-episode psychosis.
7/2012Symptom attribution in first episode psychosis: a cortical thickness study.
2/2012Medication-adherent first-episode psychosis patients also relapse: why?
9/2010Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 years.
1/2009Early predictors of nonadherence to antipsychotic therapy in first-episode psychosis.
7/2008Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls?
2/2008Insight in first episode psychosis: who is measuring what?
1/2008Validation of the alcohol use disorders identification test and the drug abuse screening test in first episode psychosis.
11/2007Substance use and abuse in first-episode psychosis: prevalence before and after early intervention.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Ashok Malla Research Topics

Disease

16Schizophrenia (Dementia Praecox)
09/2014 - 04/2002
8Psychotic Disorders (Schizoaffective Disorder)
05/2013 - 08/2003
5Substance-Related Disorders (Drug Abuse)
03/2014 - 05/2006
2Mental Disorders (Mental Disorder)
07/2012 - 02/2008
2Parkinsonian Disorders (Parkinsonism)
02/2008 - 12/2004
2Chronic Disease (Chronic Diseases)
12/2004 - 11/2002
1Learning Disorders (Learning Disability)
07/2015
1Bipolar Disorder (Mania)
01/2013
1Marijuana Abuse (Cannabis Abuse)
10/2012
1Hallucinations (Hallucination)
07/2012
1Asthma (Bronchial Asthma)
01/2009
1Insulin Resistance
07/2008
1Psychomotor Agitation (Akathisia)
02/2008
1Dyskinesias (Dyskinesia)
02/2008
1Movement Disorders (Movement Disorder)
02/2008
1Wounds and Injuries (Trauma)
12/2006
1Weight Gain
12/2005

Drug/Important Bio-Agent (IBA)

12Polytetrafluoroethylene (Teflon)FDA Link
07/2015 - 05/2005
3ziprasidone (Geodon)FDA Link
01/2013 - 06/2005
3Carbon MonoxideIBA
10/2012 - 12/2004
2Silver Sulfadiazine (SSD)FDA LinkGeneric
09/2014 - 03/2014
2Antipsychotic Agents (Antipsychotics)IBA
05/2013 - 05/2013
2CDRI 85-287 (PEPP)IBA
12/2006 - 08/2003
2olanzapine (Zyprexa)FDA Link
12/2005 - 12/2004
1Clozapine (Clozaril)FDA LinkGeneric
04/2013
1Haloperidol (Haldol)FDA LinkGeneric
08/2010
1Glucose (Dextrose)FDA LinkGeneric
07/2008
1quetiapine (Seroquel)FDA Link
02/2008
1diethylaminosulfur trifluorideIBA
01/2008
1PhosphatesIBA
03/2006
1Risperidone (Risperdal Consta)FDA LinkGeneric
12/2004
1PhosphorusIBA
05/2004
1N-acetylaspartate (N-acetyl aspartate)IBA
11/2002
1Protons (Proton)IBA
11/2002
1Glutamine (L-Glutamine)FDA Link
11/2002
1Glutamic Acid (Glutamate)FDA Link
11/2002
1SmokeIBA
04/2002

Therapy/Procedure

2Injections
05/2013 - 05/2013
1Ambulatory Care (Outpatient Care)
01/2009
1Intensive Care (Surgical Intensive Care)
01/2006